Company intelligence / Profile preview

Incisive Genetics Inc.

Vancouver, British Columbia, Canadaincisivegenetics.com ↗

Ownership: Private
Employees: ~2
Development stage: Preclinical

Overview

The company has achieved significant proof of concept data for effective in vivo gene editing and is developing its lead candidate for Huntington's disease.

Therapeutic areas: OphthalmologyNeurology
Modalities: CRISPR-based gene therapiesgene editing
Industry: Biotech

Drug pipeline

6 assets

CRISPR-based gene therapy using Incisive Delivery System

Preclinical

5 more assets in the full pipeline.

Request access →

Partnerships

Seeking partnerships with pharmaceutical companies

Beyond the preview

Go deeper on Incisive Genetics Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Incisive Genetics Inc..

Explore the full profile